Package Leaflet: Information for the User
ABILIFY 10 mg orodispersible tablets
ABILIFY 15 mg orodispersible tablets
ABILIFY 30 mg orodispersible tablets
aripiprazole
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
ABILIFY contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics. It is used to treat adults and adolescents aged 15 and older who suffer from a disease characterized by symptoms such as hearing, seeing, and feeling things that do not exist, distrust, false beliefs, incoherent speech, and emotional and behavioral monotony. People in this state may also feel depressed, guilty, restless, or tense.
ABILIFY is used to treat adults and adolescents aged 13 and older who suffer from a disorder characterized by symptoms such as feeling euphoric, having excessive energy, needing to sleep much less than usual, talking very quickly with flight of ideas, and sometimes severe irritability. In adults, it also prevents this situation in patients who have responded to treatment with ABILIFY.
Do not take ABILIFY
Warnings and precautions
Talk to your doctor before starting to take ABILIFY.
There have been reports of patients experiencing suicidal thoughts and behaviors during treatment with aripiprazole. Tell your doctor immediately if you have thoughts or feelings of harming yourself.
Before starting treatment with ABILIFY, tell your doctor if you suffer from
If you notice that you are gaining weight, developing unusual movements, experiencing drowsiness that interferes with your daily activities, having difficulty swallowing, or presenting allergic symptoms, please inform your doctor.
If you suffer from dementia (loss of memory and other mental abilities), you or the person caring for you or a family member should inform your doctor if you have ever had a stroke or a "mini" stroke.
Talk to your doctor immediately if you have thoughts or feelings of harming yourself. There have been reports of patients experiencing suicidal thoughts and behaviors during treatment with aripiprazole.
Talk to your doctor immediately if you experience numbness or stiffness of the muscles with high fever, sweating, altered mental state, or rapid or irregular heartbeat.
Tell your doctor if you, your family, or caregiver notice that you are developing impulses or urges to behave in an unusual way and cannot resist the impulse, instinct, or temptation to carry out certain activities that may harm you or others. This is called impulse control disorder and may include behaviors such as gambling addiction, excessive eating or spending, abnormally high sexual appetite, or concern about an increase in sexual thoughts and feelings.
Your doctor may consider adjusting or interrupting the dose.
Aripiprazole may cause drowsiness, low blood pressure when standing up, dizziness, and changes in the ability to move and maintain balance, which could lead to falls. You should be cautious, especially if you are an elderly patient or suffer from weakness.
Children and adolescents
Do not use this medicine in children and adolescents under 13 years of age. It is not known if it is safe and effective in these patients.
Other medicines and ABILIFY
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those without a prescription.
Medicines that lower blood pressure: ABILIFY may increase the effect of medicines used to lower blood pressure. Make sure to tell your doctor if you use any medicine to control blood pressure.
If you are taking ABILIFY with another medicine, it may mean that your doctor needs to change your dose of ABILIFY or the other medicine. It is especially important that you mention to your doctor if you are taking:
These medicines may increase the risk of side effects or reduce the effect of ABILIFY; if you notice any unusual symptoms when taking any of these medicines at the same time as ABILIFY, you should tell your doctor.
Medicines that increase serotonin levels are commonly used in diseases that include depression, generalized anxiety disorder, obsessive-compulsive disorder (OCD), and social phobia, as well as migraine and pain:
These medicines may increase the risk of side effects; if you notice any unusual symptoms when taking any of these medicines at the same time as ABILIFY, you should tell your doctor.
Taking ABILIFY with food, drinks, and alcohol
This medicine can be taken with or without food.
Alcohol consumption should be avoided.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
The following symptoms may occur in newborn babies of mothers who have been treated with ABILIFY in the last trimester of pregnancy (last three months of pregnancy): tremors, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, you should contact your doctor.
If you are taking ABILIFY, your doctor will discuss with you whether you should breastfeed, considering the benefit of treatment for you and the benefit of breastfeeding for your baby. If you are being treated with ABILIFY, you should not breastfeed. Talk to your doctor about the best way to feed your baby if you are taking this medicine.
Driving and using machines
During treatment with this medicine, dizziness and vision problems (see section 4) may occur. This should be taken into account when requiring maximum attention, for example, when driving or operating machinery.
ABILIFY contains aspartame
ABILIFY 10 mg orodispersible tablets: This medicine contains 2 mg of aspartame in each tablet.
ABILIFY 15 mg orodispersible tablets: This medicine contains 3 mg of aspartame in each tablet.
ABILIFY 30 mg orodispersible tablets: This medicine contains 6 mg of aspartame in each tablet.
Aspartame contains a source of phenylalanine that may be harmful in case of phenylketonuria (PKU),a rare genetic disease in which phenylalanine accumulates because the body is unable to eliminate it properly.
ABILIFY contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
ABILIFY contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose for adults is 15 mg once a day.However, your doctor may prescribe lower or higher doses up to a maximum of 30 mg, once a day.
Use in children and adolescents
This medicine should be started with the oral solution (liquid) at a low dose.
Gradually, the dose may be increased to the recommended dose for adolescents of 10 mg once a day. However, your doctor may prescribe lower or higher doses up to a maximum of 30 mg once a day.
If you think that the action of ABILIFY is too strong or too weak, tell your doctor or pharmacist.
Try to take ABILIFY at the same time each day. It does not matter if you take it with or without food. Do not open the blister until you are ready to take it. To take a tablet, open the package and remove the aluminum from the blister, leaving the tablet in sight. Do not press the tablet through the aluminum as this may damage it. Once the blister is open, with dry hands, take the tablet and place the entire orodispersible tablet on the tongue. The disintegration of the tablet occurs rapidly with saliva. The orodispersible tablet can be taken with or without liquid. Another option is to dissolve the tablet in water and drink the resulting suspension.
Even if you feel better, do not change or interrupt the daily dose of ABILIFY without consulting your doctor first.
If you take more ABILIFY than you should
If you realize that you have taken more ABILIFY than your doctor recommended (or if someone else has taken part of your ABILIFY), contact your doctor immediately. If you cannot contact your doctor, go to the nearest hospital and take the package with you.
Patients who have taken too much aripiprazole have experienced the following symptoms:
Other symptoms may include:
Contact your doctor or the nearest hospital immediately if you experience any of the above symptoms.
If you forget to take ABILIFY
If you forget a dose, take the forgotten dose as soon as you remember, but do not take a double dose to make up for the forgotten dose.
If you stop taking ABILIFY
Do not stop your treatment just because you feel better. It is important that you continue taking ABILIFY for the time your doctor has indicated.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Frequent adverse effects (may affect up to 1 in 10 patients):
Uncommon adverse effects (may affect up to 1 in 100 patients):
The following adverse effects have been reported during the post-marketing phase of oral aripiprazole, but the frequency of occurrence is unknown:
Inform your doctor if you experience any of these behaviors; he will explain how to manage or reduce the symptoms.
In elderly patients with dementia, a higher number of fatal cases have been reported while taking aripiprazole. Additionally, cases of stroke or "mini" stroke have been reported.
Other Adverse Effects in Children and Adolescents
Adolescents 13 years or older experienced adverse effects similar in frequency and type to those of adults, except for drowsiness, spasms, or uncontrollable contractions, restlessness, and fatigue, which were very frequent (affects more than 1 in 10 patients), and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle fasciculations, involuntary movements of the limbs, and dizziness, especially when standing up after being seated or lying down, which were frequent (affects up to 1 in 10 patients).
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
Medicines should not be thrown away through drains or into the trash. Ask your pharmacist how to dispose of packaging and medicines that are no longer needed. This will help protect the environment.
Composition of ABILIFY
Each orodispersible tablet contains 10 mg of aripiprazole.
Each orodispersible tablet contains 15 mg of aripiprazole.
Each orodispersible tablet contains 30 mg of aripiprazole.
Tablet coating
ABILIFY 10 mg orodispersible tablets: red iron oxide (E 172)
ABILIFY 15 mg orodispersible tablets: yellow iron oxide (E 172)
ABILIFY 30 mg orodispersible tablets: red iron oxide (E 172)
Appearance of ABILIFY and Package Contents
ABILIFY 10 mg orodispersible tablets are round and pink, engraved with "A" above "640" on one side and "10" on the other.
ABILIFY 15 mg orodispersible tablets are round and yellow, engraved with "A" above "641" on one side and "15" on the other.
ABILIFY 30 mg orodispersible tablets are round and pink, engraved with "A" above "643" on one side and "30" on the other.
ABILIFY orodispersible tablets are presented in single-dose blisters packaged in boxes containing 14 × 1, 28 × 1, or 49 × 1 orodispersible tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Otsuka Pharmaceutical Netherlands B.V. Herikerbergweg 292
1101 CT, Amsterdam
Netherlands
Manufacturer
Elaiapharm
2881 Route des Crêtes, Z.I. Les Bouilides-Sophia Antipolis,
06560 Valbonne
France
You can request more information about this medicine by contacting the local representative of the marketing authorization holder.
Spain
Otsuka Pharmaceutical, S.A. Tel: +34 93 550 01 00
Date of the Last Revision of this Prospectus: {MM/AAAA}
Other Sources of Information
Detailed information about this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.